Pathway Network Analyses for Autism Reveal Multisystem Involvement, Major Overlaps with Other Diseases and Convergence upon MAPK and Calcium Signaling by Wen, Ya et al.
Pathway Network Analyses
for Autism Reveal Multisystem
Involvement, Major Overlaps with
Other Diseases and Convergence
upon MAPK and Calcium Signaling
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Wen, Ya, Mohamad J. Alshikho, and Martha R. Herbert. 2016.
“Pathway Network Analyses for Autism Reveal Multisystem
Involvement, Major Overlaps with Other Diseases and Convergence
upon MAPK and Calcium Signaling.” PLoS ONE 11 (4): e0153329.
doi:10.1371/journal.pone.0153329. http://dx.doi.org/10.1371/
journal.pone.0153329.
Published Version doi:10.1371/journal.pone.0153329
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:26859887
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
RESEARCH ARTICLE
Pathway Network Analyses for Autism Reveal
Multisystem Involvement, Major Overlaps
with Other Diseases and Convergence upon
MAPK and Calcium Signaling
YaWen1,2,3*, Mohamad J. Alshikho1,2, Martha R. Herbert1,2,3*
1 TRANSCENDResearch, Neurology Department, Massachusetts General Hospital, Charlestown,
Massachusetts, United States of America, 2 Harvard Medical School, Harvard University, Boston,
Massachusetts, United States of America, 3 Higher Synthesis Foundation, Cambridge, Massachusetts,
United States of America
* ywen3@mgh.harvard.edu (YW); martha.herbert@mgh.harvard.edu (MRH)
Abstract
We used established databases in standard ways to systematically characterize gene ontolo-
gies, pathways and functional linkages in the large set of genes now associated with autism
spectrum disorders (ASDs). These conditions are particularly challenging—they lack clear
pathognomonic biological markers, they involve great heterogeneity across multiple levels
(genes, systemic biological and brain characteristics, and nuances of behavioral manifesta-
tions)—and yet everyone with this diagnosis meets the same defining behavioral criteria.
Using the human gene list fromSimons Foundation AutismResearch Initiative (SFARI) we per-
formed gene set enrichment analysis with the Kyoto Encyclopedia of Genes and Genomes
(KEGG) Pathway Database, and then derived a pathway network from pathway-pathway func-
tional interactions again in reference to KEGG. Through identifying the GO (GeneOntology)
groups in which SFARI genes were enriched, mapping the coherence between pathways and
GO groups, and ranking the relative strengths of representation of pathway network compo-
nents, we 1) identified 10 disease-associated and 30 function-associated pathways 2) revealed
calcium signaling pathway and neuroactive ligand-receptor interaction as themost enriched,
statistically significant pathways from the enrichment analysis, 3) showed calcium signaling
pathways and MAPK signaling pathway to be interactive hubs with other pathways and also to
be involved with pervasively present biological processes, 4) found convergent indications that
the process “calcium-PRC (protein kinase C)-Ras-Raf-MAPK/ERK” is likely a major contributor
to ASD pathophysiology, and 5) noted that perturbations associated with KEGG’s category of
environmental information processing were common. These findings support the idea that
ASD-associated genes may contribute not only to core features of ASD themselves but also to
vulnerability to other chronic and systemic problems potentially including cancer, metabolic
conditions and heart diseases. ASDsmay thus arise, or emerge, from underlying vulnerabilities
related to pleiotropic genes associated with pervasively important molecular mechanisms, vul-
nerability to environmental input andmultiple systemic co-morbidities.
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Introduction
While there remains controversy regarding the relative contributions of artifact and true
increase to the rising prevalence of ASDs, there is no question that these spectrum conditions
have major human, public health and economic impacts. They also pose major challenges to
research, since while ASDs are defined by social impairments, communication difficulties, and
restricted, repetitive, and stereotyped patterns of behavior, there are no pathognomonic biolog-
ical features universally present in people meeting the behavior-level diagnostic criteria, and
many other biological features have been identified in subgroups both in the brain and systemi-
cally whose contributions to the development and ongoing characteristics of ASDs are not
clearly understood.
As of December 2014, the SFARI Gene-Human Gene Module recorded 667 human genes
implicated as relevant to ASDs. These genes are widely expressed and are involved in a variety
of biological activities. To make full biological sense of this large number and diversity of
genes, it is important both to consider the full range of their biological activities, and to identify
processes with higher likelihood of substantial relevance to ASDs.
In this study we chose to consider the accumulated set of genes as a whole, and to utilize
established databases and analytical processes to seek patterns and connections within this
large aggregate. To do this we expanded the framework from just genes to also include the con-
texts, reactions and processes in which they participate. We used enrichment analysis to iden-
tify 1) pathways in which ASD-associated genes were over-represented, 2) biological features
for which ASD-associated genes were particularly present, and 3) overlaps and convergences
amongst the several types of analyses that we performed. Future studies may add more nuances
to the analyses we report, including addressing biases that may be present at various stages of
the process ranging at least from gene discovery to database construction. For the present
study we did not introduce any biases from favoring certain types of biological processes or
domains over others, and we did not utilize any weighting systems, as we could not locate any
established or fully developed weighting methods that could do justice to all the different varie-
ties of ASDs, considering the marked heterogeneity this diagnosis encompasses. We aimed
simply to let the data speak through the patterns and relationships that emerged from perform-
ing standard analyses, regardless of whether the resultant findings were consistent with areas of
predominant focus in the existing literature. To our knowledge the aggregate of genes associ-
ated with ASD, along with their functions, contexts and pathway networks, have not previously
been analyzed in this manner.
The networks in which cellular processes often function, which involve sets of gene products
acting in concert, can be mapped as pathways. Since there are many overlaps among pathways,
identifying convergent molecular pathways in which multiple candidate genes are involved has
been discussed for years [1], as this may be an effective way to gain insight into the underlying
molecular basis of ASDs. There are a number of studies that aim to discern potential important
pathways to ASDs, whether by developing protein interaction networks [2,3] or gene co-
expression networks [4], or by identifying specific affected pathways from ASD genetic data-
bases [5]. However, there are very few studies that have systematically investigated pathways or
pathway networks that may link to ASDs, and to our knowledge there are no prior studies
looking at pathway-pathway interactions at the functional level in ASDs.
In this study we developed an ASD pathway network and performed a systematic analysis
of the network. With this approach we aimed to expand our understanding to include not only
genes but also the function of gene products, as well as the networking of reactions and interac-
tions. In thus generating a coordinated presentation whose depictions take account of gene-
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pathway coherence, pathway-pathway interactions, and disease-disease relationships, our
objective was to provide a framework and clues for further investigations.
Materials and Methods
Gene set enrichment analysis
To identify a variety of pathways and biological signatures, we investigated enrichment within
the Human Gene Module of SFARI Gene. ASD genes were downloaded from SFARI Gene–
Human Gene (https://gene.sfari.org/autdb/HG_Home.do, S1 Table), and investigated in the
freely available Molecular Signatures Database, MSigDB [6] v4.0 (http://www.broadinstitute.
org/gsea/msigdb/index.jsp). We applied the “Compute Overlaps” tool fromMSigDB website,
under “Investigate gene sets” category, which uses the hypergeometric distribution to examine
how SFARI genes and other gene sets may overlap. Gene symbol was used as gene identifier to
import the gene set. MSigDB is a collection of annotated gene sets for use with Gene Set
Enrichment Analysis (GSEA) software [6]. Here we used the MSigDB collections derived from
the KEGG Pathway Database (http://www.genome.jp/kegg/pathway.html) and the GO Con-
sortium (http://geneontology.org/). The GO dataset provides a central collection of the attri-
butes already known and assigned to specific genes.
Overlaps and ranking
The overlaps between SFARI genes and KEGG gene sets (derived from the KEGG pathway
database and each of the sub-collections of GO gene sets, (i.e., the Biological Processes (BP),
cellular component (CC) and molecular function (MF) ontologies), were computed individu-
ally. Data obtained from this procedure can be found in S2 Table; the top 50 enriched gene sets
with false discovery rate (FDR) q-value below 0.05 were listed, ranked by p-values (low to
high). GSEA allows us to choose the enriched groups from top 10, 20, 50, and 100. We made
the judgment to choose 50 because it is a moderate number for pathway network analysis–
large enough to build an interaction network and small enough to avoid overly diluting the
ASD specificity of the genes. Further information regarding the “Compute Overlaps” tool can
be found on the “Help” page under Molecular Signatures Database, under “Help with Investi-
gating Gene Sets” here: http://software.broadinstitute.org/gsea/msigdb/help_annotations.jsp—
overlap (one needs to register and login to use this link).
Redundancy control for the enriched pathways
Highly overlapped pathways may cause redundancy, and this might bias the results of analysis.
To minimize the impact of such redundancy among our gene sets, Redundancy Control in
Pathway Databases (ReCiPa) [7] was applied to the top 50 pathways resulting from the enrich-
ment analysis. The ReCiPa package was downloaded from the url described in the original
paper (http://cran.r-project.org/web/packages/ReCiPa/) and installed and loaded in R (http://
www.r-project.org/). The KEGG pathway database file was downloaded from MSigDB Down-
loads (http://www.broadinstitute.org/gsea/downloads.jsp). We used the enriched 50 KEGG
pathways as our input database. Highly overlapped pathways were merged into collections (set-
ting Max = 0.85, Min = 0.10). For each merged collection, the p-value from the dominant path-
way (pathways with lowest p-values) was used as the p-value for the particular collection.
Pathway-pathway and pathway-gene interactions
In cells, pathways interact with each other rather like street-meets-street in a city map. In order
to obtain a systems overview of how these pathways function together, it is of great value to
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generate a pathway network, which can be done by taking account of the connections/interac-
tions between pathways. One pathway may interact with another for multiple reasons: shared
genes or compounds, interactions or reactions between genes or compounds, signal transduc-
tions, etc. We chose to work with KEGG Pathway Database, which documents these many
types of influences and interactions, to help us generate this pathway network overview,
because it is a comprehensive and frequently updated database that represents our present
knowledge of pathways and the known interactions amongst pathways based on accumulated
research findings. Pathway-pathway interactions are represented in KEGG in each pathway
map by displaying the name of an interacting pathway in that map. For example, if one path-
way appears at the certain location in the map of another pathway, this suggests that these two
pathways were interacting in relation to the activities or functions represented in that part of
the map, or that one was involved in a certain reaction or process of another. On this basis, we
determined the pathway-pathway interactions by tabulating these instances. For the merged
collections, if one pathway not in the collection interacted with at least one of the pathways in
the collection, this pathway was considered to be interacting with the collection. For the path-
way “pathways in cancer” (http://www.genome.jp/kegg-bin/show_pathway?map05200, or go
to KEGG, search for “pathways in cancer”, and find the map05200), other cancer pathways
(such as “glioma”, “thyroid cancer” etc.) which were listed on the bottom of the KEGG pathway
map, did not count as interacting with the “pathways in cancer”, as they are not actually inter-
acting with each other but only being listed in the map.
For pathway-pathway interactions, the total number of interactions was tabulated for each
pathway/collection (S3 Table), and then visualized in a network diagram.
To investigate pathway-gene interactions characterizing the involvement of each ASD gene
in the pathway network, the number of pathways in which each gene participates was counted,
and the total number of pathways was tabulated for each gene.
Pathway network analyses
We then examined the pathway network for patterns of more significant or common interac-
tions and functional impacts, aiming to highlight ways that these pathways and processes
might particularly contribute to ASD pathology at the function level. We examined the path-
way network to identify any “hub” (most interactive) pathways, most involved genes, possible
links between the pathway network and GO groups. Then we looked for any convergences
between the predominant pathways, genes and GO groups thereby identified. Out of this
examination we identified and depicted convergent mechanisms.
Results
Most enriched pathways
659 out of 667 ASD genes from SFARI Genes were identified inMSigDB v4.0. We did not
include those genes that were not identified inMSigDB in our analysis. The top 50 enriched path-
ways (from the 659 genes) were chosen from the computation of overlaps with KEGG gene sets
(S2 Table). These top 50 pathways were sorted by p-values regarding significance of overlaps; the
“calcium signaling pathway” (p-value 2.84E-29) and “neuroactive ligand-receptor interaction”
(p-value 2.87E-29) stand out with their markedly stronger statistical significance (S2 Table).
Enriched pathways groupings and redundancy reduction
The KEGG Pathway Database contains diversely named pathways that overlap with one
another to varying degrees. In our data, among our 50 pathways, we identified 13 enriched
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cancer pathways that might overlap amongst themselves at multiple levels. The application of
ReCiPa [7] merged highly overlapped pathways and generated two collections. By merging 2
cardiac disease pathways a single collection cardiac disease was generated, and by merging 10
cancer pathways a single collection cancer was generated. The final yield from 50 pathways was
a list of 40 pathways/collections, which we used for further analysis (Table 1).
Subgrouping of pathways/collections
We subdivided the 40 pathways/collections into 30 function-related pathways and 10 disease-
related pathways, and further sub-grouped them according to their characteristics (Table 1):
1. The 30 function-related pathways were sub-grouped into 5 sub-categories: cell signaling
(encompassing 9 pathways under 3 groups: signal transduction, signaling molecules and inter-
action), cell structure/transport (encompassing 5 pathways under 3 groups: cell motility, com-
munication and cellular transport), metabolism (encompassing 8 pathways under 3 groups:
amino acid metabolism, protein degradation, and synthesis), neural (encompassing 5 path-
ways with no subgroups), and immune (encompassing 3 pathways with no subgroups).
2. The ten disease-related pathways/collections were sub-grouped into 4 sub-categories: cancer
(4 of 10), cardiac disease (2 of 10), metabolic diseases (1 of 10) and neurodegenerative dis-
eases (3 of 10).
Fig 1 displays the proportional contribution of pathway groups and subgroups to the overall
ASD pathway network, and shows that the largest proportions of pathways were contributed
by the cell signaling subgroup in the function-related pathways group and the collection cancer
in the disease-related pathways group.
Gene Ontology grouping and overlaps between most enriched pathways
The results of ASD gene enrichment analysis in MSigDB with GO gene sets were divided into
three GO groups: biological processes (BP) (most enriched for “nervous system development”,
p-value 2.08E-61), cellular components (CC) (most enriched for “plasma membrane” p-value
1.19E-60), and molecular functions (MF) (most enriched for “receptor activity”, p-value 3.07E-
28) (Table 2).
We noted that the three top enriched GO categories together contain one of the two above-
mentioned most significant pathways, “neuroactive ligand-receptor interaction,” which is
indeed involved in the “nervous system”, functions on “plasma membrane” and relates to
“receptor activities”; that is, the most enriched pathway coincides with the most enriched GO
groups in BP, CC and MF.
Pathway-pathway interactions
We used the number of interactions a pathway has with other pathways in an overall network
as an indicator of its level of involvement in the pathway network; this of course involves mak-
ing a working assumption about the relevance of number of interactions to overall involve-
ment; we proceeded in this way in order to generate hypotheses that will need to be tested by
future investigations such as biological experiments and clinical studies. To display the results
of the present analyses aimed at generating a provisional metric of extent of involvement of
each pathway in the overall ASD pathway network we presented the counts of how many inter-
actions each pathway in this network had with other pathways in the network, and evaluated
the level of involvement of each pathway by the number of interactions it has (Table 1 and S3
Table).
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Table 1. Pathway groupings and pathway-pathway interactions.
Description Interactions ASD
genes
P-values # (%)
Pathways
Functional pathways 30 (75%)
Cell signaling 9 (22.5%)
Calcium signaling pathway 12 35 2.84E-29
MAPK signaling pathway 20 22 6.59E-11
Cell adhesion molecules (CAMs) 1 16 1.14E-10
Wnt signaling pathway 9 15 5.70E-09
mTOR signaling pathway 4 10 3.16E-09
Vascular smooth muscle contraction 1 14 1.28E-09
ErbB signaling pathway 5 11 5.07E-08
ECM-receptor interaction 4 10 3.66E-07
GnRH signaling pathway 3 10 2.05E-06
Cell structure / Transport 5 (12.5%)
Focal adhesion 5 21 1.98E-12
Gap junction 4 14 4.50E-11
Regulation of actin cytoskeleton 8 18 2.97E-09
Adherens junction 5 11 1.04E-08
Endocytosis 0 15 7.61E-08
Metabolism 8 (20%)
Melanogenesis 4 16 1.62E-12
Lysine degradation 1 8 1.93E-07
Ubiquitin mediated proteolysis 6 13 1.11E-07
Tyrosine metabolism 2 7 2.11E-06
Phenylalanine metabolism 1 5 4.38E-06
Aldosterone-regulated sodium reabsorption 1 7 2.11E-06
Tryptophan metabolism 0 7 1.49E-06
Arginine and proline metabolism 1 7 1.19E-05
Neural 5 (12.5%)
Neuroactive ligand-receptor interaction 2 41 2.87E-29
Long-term potentiation 3 17 1.46E-16
Neurotrophin signaling pathway 4 17 4.06E-12
Long-term depression 1 11 4.88E-09
Axon guidance 2 13 4.96E-08
Immune 3 (7.5%)
Leukocyte transendothelial migration 3 10 8.35E-06
Chemokine signaling pathway 4 12 2.19E-05
B cell receptor signaling pathway 4 8 1.24E-05
Disease Pathways 10 (25%)
Cancer 4 (10%)
Collection cancer: Acute myeloid leukemia, Bladder cancer, Chronic myeloid leukemia,
Colorectal cancer, Endometrial cancer, Melanoma, Non-small cell lung cancer, Pathways in
cancer, Prostate cancer, Small cell lung cancer
9 37 2.95E-18
Renal cell carcinoma 2 11 4.88E-09
Thyroid cancer 3 7 1.43E-07
Glioma 4 8 4.21E-06
Cardiac disease 2 (5%)
Arrhythmogenic right ventricular cardiomyopathy (ARVC) 3 12 9.21E-10
Collection cardiac disease: Dilated cardiomyopathy, Hypertrophic cardiomyopathy (HCM) 1 13 7.64E-10
(Continued)
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Based upon this information regarding significance and connections between pathways
contained in KEGG pathway maps, we generated a pathway-pathway interaction map by con-
necting all the pairs of interacting pathways and indicating significance by size and color of cir-
cles (Fig 2).
ASD pathway network hub: MAPK signaling
The MAPK (mitogen-activated protein kinases, also known as ERK, extracellular signal-regu-
lated kinases) signaling pathway interacts with half of the pathways in the network (20/40,
Table 1. (Continued)
Description Interactions ASD
genes
P-values # (%)
Pathways
Metabolic disease 1 (2.5%)
Type II diabetes mellitus 0 8 3.29E-07
Neurodegenerative disease 3 (7.5%)
Alzheimer's disease 2 13 1.15E-06
Amyotrophic lateral sclerosis (ALS) 1 7 1.05E-05
Huntington's disease 1 12 1.68E-05
Interactions = number of other pathways in the network with which each pathway interacted. ASD genes = number of ASD genes in each pathway. #(%)
Pathways = number of pathways in each group and that group’s percentage of the total network. Most signiﬁcant pathways are indicated in bold.
Collections are indicated in italic.
doi:10.1371/journal.pone.0153329.t001
Fig 1. Pathway groupings. Pathways were grouped into subsets of two classes. Pathways in the Disease
class are surrounded by a black border; the remainder of the pie chart sections are in the Functional class.
Labels indicate pathway groupings (number of pathways in grouping/percentage of total number of
pathways).
doi:10.1371/journal.pone.0153329.g001
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Table 2. Enrichment analyses for gene ontologies.
Genes in gene set ASD genes P-value FDR
q-value
Biological Processes Gene Set Names
NERVOUS_SYSTEM_DEVELOPMENT 385 75 2.08E-61 1.72E-58
MULTICELLULAR_ORGANISMAL_DEVELOPMENT 1049 100 1.58E-51 6.50E-49
SYSTEM_DEVELOPMENT 861 91 1.29E-50 3.55E-48
ANATOMICAL_STRUCTURE_DEVELOPMENT 1013 96 3.30E-49 6.80E-47
SIGNAL_TRANSDUCTION 1634 106 4.95E-39 8.17E-37
SYSTEM_PROCESS 563 57 7.73E-31 1.06E-28
CENTRAL_NERVOUS_SYSTEM_DEVELOPMENT 123 30 2.94E-28 3.46E-26
BIOPOLYMER_METABOLIC_PROCESS 1684 92 3.38E-28 3.48E-26
NEUROLOGICAL_SYSTEM_PROCESS 379 45 1.78E-27 1.63E-25
CELL_DEVELOPMENT 577 52 8.13E-26 6.71E-24
TRANSMISSION_OF_NERVE_IMPULSE 189 32 9.78E-25 7.33E-23
SYNAPTIC_TRANSMISSION 174 30 1.64E-23 1.13E-21
BIOPOLYMER_MODIFICATION 650 50 8.04E-22 5.10E-20
CELL_CELL_SIGNALING 404 40 1.33E-21 7.68E-20
PROTEIN_MODIFICATION_PROCESS 631 49 1.40E-21 7.68E-20
Cellular Components Gene Set Names
PLASMA_MEMBRANE 1426 125 1.19E-60 2.77E-58
PLASMA_MEMBRANE_PART 1158 112 1.62E-58 1.88E-56
MEMBRANE 1994 142 7.02E-58 5.45E-56
MEMBRANE_PART 1670 127 1.23E-54 7.15E-53
INTRINSIC_TO_PLASMA_MEMBRANE 991 91 1.78E-45 8.31E-44
INTEGRAL_TO_PLASMA_MEMBRANE 977 90 4.39E-45 1.70E-43
INTRINSIC_TO_MEMBRANE 1348 102 2.20E-43 7.31E-42
INTEGRAL_TO_MEMBRANE 1330 100 2.81E-42 8.19E-41
CYTOPLASM 2131 112 6.37E-33 1.65E-31
CYTOPLASMIC_PART 1383 75 7.47E-23 1.74E-21
PROTEIN_COMPLEX 816 53 9.26E-20 1.96E-18
MACROMOLECULAR_COMPLEX 945 57 1.14E-19 2.21E-18
NUCLEUS 1430 71 1.47E-19 2.64E-18
CYTOSKELETON 367 31 4.18E-15 6.96E-14
INTRACELLULAR_ORGANELLE_PART 1192 56 1.31E-14 2.03E-13
Molecular Functions Gene Set Names
RECEPTOR_ACTIVITY 583 55 3.07E-28 1.21E-25
TRANSMEMBRANE_RECEPTOR_ACTIVITY 418 43 8.59E-24 1.70E-21
G_PROTEIN_COUPLED_RECEPTOR_ACTIVITY 191 22 7.92E-14 9.15E-12
PHOSPHOTRANSFERASE_ACTIVITY_ALCOHOL_GROUP_AS_ACCEPTOR 334 28 1.08E-13 9.15E-12
PROTEIN_KINASE_ACTIVITY 285 26 1.16E-13 9.15E-12
KINASE_ACTIVITY 369 29 2.02E-13 1.34E-11
IDENTICAL_PROTEIN_BINDING 304 26 5.18E-13 2.93E-11
RHODOPSIN_LIKE_RECEPTOR_ACTIVITY 134 18 1.02E-12 5.07E-11
CATION_CHANNEL_ACTIVITY 119 17 1.57E-12 6.92E-11
GATED_CHANNEL_ACTIVITY 122 17 2.38E-12 9.42E-11
METAL_ION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY 147 18 5.09E-12 1.83E-10
TRANSFERASE_ACTIVITY_TRANSFERRING_PHOSPHORUS_CONTAINING_GROUPS 424 29 6.34E-12 1.96E-10
ION_CHANNEL_ACTIVITY 149 18 6.42E-12 1.96E-10
(Continued)
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Table 1), making this pathway the most inter-connected pathway in our map; within the terms
of our analytical framework this identifies it as the main hub among the enriched pathways.
Prominence of calcium signaling dysregulation
Calcium signaling pathway is not only the most enriched pathway but also very interactive in
the ASD pathway network: it is the second most interactive pathway, interacting with 12 out of
40 pathways (Table 1). ASD genes in the calcium signaling pathway (PRKCB, PLCB1,
Table 2. (Continued)
Genes in gene set ASD genes P-value FDR
q-value
TRANSMEMBRANE_TRANSPORTER_ACTIVITY 375 27 1.05E-11 2.97E-10
SUBSTRATE_SPECIFIC_CHANNEL_ACTIVITY 156 18 1.41E-11 3.71E-10
CYTOSKELETAL_PROTEIN_BINDING 159 18 1.94E-11 4.81E-10
Genes in gene set = total number of genes in the gene set. ASD genes = number of ASD genes in the gene set.
doi:10.1371/journal.pone.0153329.t002
Fig 2. ASD pathway network. Pathways are grouped vertically under two classes, Disease and Function. The color of each node within the groupings
represents the p-value of that pathway. The size of each node represents the number of ASD genes in that pathway. Interactions between pairs of pathways
are indicated by edges. The pathway-pathway interaction matrix is in S3 Table.
doi:10.1371/journal.pone.0153329.g002
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CACNA1C, CACNA1D, and CACNA1F) are also highly involved in the pathway network, par-
ticipating in 7–17 out of 40 pathways (Table 3). Additionally, Ca2+ (calcium ion) participates
in 23 out of the 40 enriched pathways in reference to KEGG (http://www.genome.jp/dbget-
bin/www_bget?C00076, or go to KEGG and search for C00076 –the compound number for
calcium ion in KEGG).
Genes with most participation in pathways
To investigate the involvement of each ASD gene in the pathway network, we counted the
number of pathways in which each gene participates (Table 3). We found thatMAPK1 (ERK2),
Table 3. Involvement of ASD genes in the ASD pathway network.
Gene Symbol Gene Description # Pathways
MAPK1 mitogen-activated protein kinase 1 23
MAPK3 mitogen-activated protein kinase 3 23
HRAS v-Ha-ras Harvey rat sarcoma viral oncogene homolog 18
PRKCB protein kinase C, beta 17
BRAF v-raf murine sarcoma viral oncogene homolog B1 14
PIK3CG phosphoinositide-3-kinase, catalytic, gamma polypeptide 13
PIK3R2 phosphoinositide-3-kinase, regulatory subunit 2 (beta) 13
PLCB1 phospholipase C, beta 1 (phosphoinositide-speciﬁc) 11
GSK3B glycogen synthase kinase 3 beta 10
CACNA1C calcium channel, voltage-dependent, L type, alpha 1C subunit 9
CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa 8
CACNA1D calcium channel, voltage-dependent, L type, alpha 1D subunit 8
CACNA1F calcium channel, voltage-dependent, L type, alpha 1F subunit 7
CREBBP CREB binding protein 7
EP300 E1A binding protein p300 7
ITGA4 integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) 7
GNAS GNAS complex locus 7
TCF7L2 transcription factor 7-like 2 (T-cell speciﬁc, HMG-box) 6
MET met proto-oncogene (hepatocyte growth factor receptor) 6
ITGB7 integrin, beta 7 6
GRM5 glutamate receptor, metabotropic 5 6
GRIN1 glutamate receptor, ionotropic, N-methyl D-aspartate 1 6
ADCY5 adenylate cyclase 5 5
ITGB3 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 5
GRM1 glutamate receptor, metabotropic 1 5
GRIN2A glutamate receptor, ionotropic, N-methyl D-aspartate 2A 5
GRIN2B glutamate receptor, ionotropic, N-methyl D-aspartate 2B 5
NTRK1 neurotrophic tyrosine kinase, receptor, type 1 4
BCL2 B-cell CLL/lymphoma 2 4
CTNNA3 catenin (cadherin-associated protein), alpha 3 4
RPS6KA2 ribosomal protein S6 kinase, 90kDa, polypeptide 2 4
RPS6KA3 ribosomal protein S6 kinase, 90kDa, polypeptide 3 4
MAOA monoamine oxidase A 4
MAOB monoamine oxidase B 4
# Pathways = number of pathways (in the autism pathway network) in which each gene participates.
Table only displays those genes participating in more than 4 pathways.
doi:10.1371/journal.pone.0153329.t003
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MAPK3 (ERK1), HRAS, PRKCB and BRAF are the most involved genes, in that they participate
in 14–23 out of 40 enriched pathways/collections.
Coherence between pathway with most interactions and genes with
maximal participation
In addition to finding that the MAPK pathway has the highest number of interactions with
other pathways in our pathway-pathway interaction map, we also noted that the above-listed
genes we separately identified using MSigDB as involved in the most enriched pathways are all
according to KEGG Pathway Database specifically involved in the MAPK signaling pathway.
We interpreted this coherence across genes, pathways and methodologies as suggesting a very
high level of involvement of the MAPK signaling pathway, together withMAPK/ERK genes, in
the ASD pathway network.
Integrated MAPK and calcium signaling
We further noted that MAPK and calcium signaling pathways overlapped via 8 ASD genes:
CACNA1H, CACNA1G, CACNA1I, CACNA1D, CACNA1B, CACNA1C, CACNA1F, and
PRKCB (Fig 3A).
Looking at the function of these overlapping genes can aid in understanding the potential
integrated functions of MAPK and calcium signaling, CACNA1s genes encode a group of pro-
teins in the family of voltage-gated calcium channel alpha 1 subunits. The PRKCB gene encodes
protein kinase C (PKC), beta. PKC is a family of serine- and threonine-specific protein kinases
that can be activated by calcium and diacylglycerol (DAG) [8]. Based on the common ASD
genes in the MAPK and calcium signaling pathways (CACNA1s and PRKCB), we narrowed
down the overlapping function of these two pathways in ASDs to voltage-gated calcium chan-
nels and calcium activated PKC. Calcium channels in many cell types mediate calcium influx
in response to action potentials. An increase in concentration of calcium activates PKC, which
regulates Ras and Raf1 proteins by phosphorylation [9]. Once activated, Ras proteins bind to
and activate the protein kinase activity of Raf kinases, which phosphorylates and activates
MEK (Mitogen-activated protein kinase, MEK1 and MEK2). MEK Phosphorylates and acti-
vates MAPK. [10] (Fig 3B). In our ASD pathway network, the top 5 highly involved genes—
MAPK1 (ERK2),MAPK3 (ERK1),HRAS, PRKCB and BRAF—encode the proteins MAP kinase
1, MAP kinase 3, small GTPase H-Ras, PKC, and serine/threonine protein kinase B-Raf;
together they function in the PKC-Ras-Raf-MAPK/ERK process.
This contextual information allows us to discern that the overlapping ASD genes in the
MAPK and calcium signaling pathways, together with most involved ASD pathway network
genes, function in the following sequential process whose pertinent highlights include: calcium
channel mediates calcium influx, and increased calcium level activates PKC, leading conse-
quently to the Ras-Raf-MEK-MAPK/ERK cascade.
Taken together, integrated analysis for MAPK and calcium signaling pathways came
together in the process “calcium-PKC-Ras-Raf-MAPK/ERK”.
Discussion
In this study we performed a descriptive investigation of the relationships between a large set
of ASD-associated genes, the pathways and functions in which these genes participate, and the
interactions amongst the pathways. We made every effort to eliminate bias, by using only
established and freely available databases and established analytics for utilizing them, and by
letting the data generated by these analyses speak for themselves rather than weighting the data
on the basis of any a priori assumptions or as yet incomplete weighting systems. We present
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our findings as a kind of “demographics” of ASD-associated genes with the hope of generating
hypotheses for further investigation, some of which might not otherwise have emerged from
the diverse range of ASD genetic data and the analytic approaches currently in use.
The pathway map we generated shows marked interactions amongst the genes and path-
ways, and participation of pathways with a broad range of functions and diseases by no means
Fig 3. Integrated MAPK and calcium signaling in ASDs. a. Overlapping genes in calcium and MAPK
signaling pathways. b. The voltage-gated calcium channel mediates the influx of Ca2+, which modulates PKC
and Ras. Growth factors bind to the extracellular domain of receptor tyrosine kinases (RTKs), and signal
molecules Grb2 (growth factor receptor-bound protein 2) and Sos (son of sevenless) are consequently
recruited to the internal docking site, resulting in Ras activation. Ras triggers a phosphorylation cascade
including Raf and MEK. This leads to ERK activation and translocation to the nucleus, where ERK then
activates transcription factors that mediate gene expression. The ASD genes are listed in light blue frames
close to the corresponding gene products that are shown in orange.
doi:10.1371/journal.pone.0153329.g003
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limited to those (such as neurological diseases or development) most commonly considered as
centrally relevant to ASD. Although our findings were generated through several separate anal-
yses, we were struck by the convergent findings that emerged from these different approaches.
Two pathways stood out most strongly amongst the pathways in which the SFARI ASD-associ-
ated genes participated: the MAPK signaling pathway which was the most highly interactive,
and the calcium signaling pathway, which was the most highly enriched pathway. Of further
interest, based on our pathway-gene interaction analyses, the 8 genes that overlap between the
MAPK and calcium signaling pathways are involved in the process “calcium-PKC-Ras-Raf-
MAPK/ERK”. What might these findings suggest about possible underlying mechanisms and
vulnerabilities in ASDs?
Diversity of pathway groupings
Amongst the functional pathway groupings, it was interesting to note that there was greater
proportional involvement of pathways associated with cell signaling and with metabolism than
of pathways associated with nervous system or immune function. Even so, we did find a ner-
vous system pathway, “neuroactive ligand-receptor interaction” as well as a nervous system
GO category, “nervous system development”, to be among the most enriched pathways and
GO groups, respectively, which is consistent with the predominant emphasis on nervous sys-
tem development in ASD research and clinical practice. Nevertheless, the diversity of pathway
groupings and patterns of proportional involvement suggest that the clinically strongly appar-
ent neuropsychiatric phenotypic features in ASDs may be supplemented and potentially signif-
icantly driven by underlying more pervasive processes that are not specific to ASD brain or
behavior features–nor for that matter to the increasingly appreciated immune system features
of ASDs.
Amongst the disease pathways enriched for ASD genes, we found overlaps with several
categories of chronic illness. This observation raises intriguing questions about shared under-
lying vulnerabilities for these various types of diseases some of which also show at least
apparent increases, and may shed some light on the mechanisms underlying that portion of
increases in prevalence of ASDs that cannot be explained away by increased awareness,
changes in diagnostic criteria, earlier age at diagnosis, diagnostic substitution or other con-
founds [11,12].
Diversity and overlaps of Gene Ontology groups
The range of involved GO Gene Sets within each of GO groups is also striking, and again sug-
gests that a broad range of processes may contribute to ASD pathogenesis, though clearly not
all at the same time in every single person carrying the ASD diagnostic label. The convergence
of the most enriched GO categories in each of the three GO groups with the “neuroactive
ligand-receptor interaction” pathway is one of several pointers to potential common underly-
ing mechanisms that our investigation uncovered. Notably, many ASD genes that participate
in this pathway encode receptors for neurotransmitters such as serotonin, dopamine, gamma-
aminobutyric acid (GABA), glutamate and oxytocin, all of which have documented relation-
ships to ASDs (Table 4) [13]. This suggests that the abnormalities in ASDs related to such neu-
rotransmitters may arise at least in part from dysfunction of their receptor activities. This
convergence also suggests that the neuroactive ligand-receptor activities on the plasma mem-
brane, perhaps particularly during nervous system development, might be critical for promot-
ing both the development of ASDs and the ongoing brain dysfunctions associated with the
condition.
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Pathway-pathway interactions, network hubs and cancer
Although it is intriguing and surprising that the most represented disease pathway / collection
in our ASD pathway network is cancer pathways, other methodologies have identified multi-
functional genes associated with both cancer and nervous system development or disease
Table 4. ASD genes in the pathway neuroactive ligand-receptor interaction.
Gene Symbol Gene Description
GRM5 glutamate receptor, metabotropic 5
GRM1 glutamate receptor, metabotropic 1
GRIN1 glutamate receptor, ionotropic, N-methyl D-aspartate 1
GRIN2A glutamate receptor, ionotropic, N-methyl D-aspartate 2A
DRD1 dopamine receptor D1
HTR2A 5-hydroxytryptamine (serotonin) receptor 2A
ADORA2A adenosine A2a receptor
AVPR1A arginine vasopressin receptor 1A
CHRM3 cholinergic receptor, muscarinic 3
ADRB2 adrenergic, beta-2-, receptor, surface
CHRNA7 cholinergic receptor, nicotinic, alpha 7
GRPR gastrin-releasing peptide receptor
HTR7 5-hydroxytryptamine (serotonin) receptor 7 (adenylate cyclase-coupled)
OXTR oxytocin receptor
P2RX4 purinergic receptor P2X, ligand-gated ion channel, 4
PTGER3 prostaglandin E receptor 3 (subtype EP3)
GRIN2B glutamate receptor, ionotropic, N-methyl D-aspartate 2B
DRD2 dopamine receptor D2
GRID2 glutamate receptor, ionotropic, delta 2
LEP leptin
GRM4 glutamate receptor, metabotropic 4
AGTR2 angiotensin II receptor, type 2
CHRNB3 cholinergic receptor, nicotinic, beta 3
CNR1 cannabinoid receptor 1 (brain)
CNR2 cannabinoid receptor 2 (macrophage)
ADORA3 adenosine A3 receptor
DRD3 dopamine receptor D3
GABRA1 gamma-aminobutyric acid (GABA) A receptor, alpha 1
GABRA3 gamma-aminobutyric acid (GABA) A receptor, alpha 3
GABRA4 gamma-aminobutyric acid (GABA) A receptor, alpha 4
GABRB1 gamma-aminobutyric acid (GABA) A receptor, beta 1
GABRB3 gamma-aminobutyric acid (GABA) A receptor, beta 3
GLRA2 glycine receptor, alpha 2
GRID1 glutamate receptor, ionotropic, delta 1
GRIK2 glutamate receptor, ionotropic, kainate 2
GRM8 glutamate receptor, metabotropic 8
HTR1B 5-hydroxytryptamine (serotonin) receptor 1B
MC4R melanocortin 4 receptor
OPRM1 opioid receptor, mu 1
GABRQ gamma-aminobutyric acid (GABA) receptor, theta
THRA thyroid hormone receptor, alpha
doi:10.1371/journal.pone.0153329.t004
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[14–16]. The significance of MAPK signaling in our findings may contribute a bit more to
understand how ASD and cancer might be associated.
The single most interactive pathway in the ASD Pathway Network, MAPK signaling path-
way (also known as Ras-Raf-MEK-ERK pathway), has a diverse range of relationships to func-
tions and diseases. It is involved in a variety of fundamental cellular processes such as
proliferation, differentiation, migration, stress response, and apoptosis [10,17]. It is extensively
researched in cancer studies, as abnormalities in MAPK signaling play a critical role in the
development of cancer [18]. Lately, MAPK signaling has been discussed in ASDs [1] and sev-
eral recent studies have supported a link between MAPK signaling and ASD traits [19–22].
Also of note is that the important role of MAPK signaling in cancer also coincides with our
findings of significantly enriched and interactive cancer pathways—collection cancer, which
participates in the ASD pathway network (Fig 2).
It is worth considering what the biological overlap might be between ASD and cancer, specifi-
cally given the involvement of MAPK signaling. We would suggest that metabolism might bridge
this apparently large gap. Our chain of reasoning here includes the following considerations: 1)
MAPK signaling plays an important role in metabolism: it responds to changes in the extracellular
or intracellular milieu that often affect the metabolism of the cell; in this regard, altered MAPK sig-
naling has been associated with metabolic syndrome [23]. 2) In our ASD pathway network, there
are 8 functional metabolism pathways and 1 metabolic disease pathway, which together constitute
22.5% of the network (Table 1, Fig 1). 3) Moreover, metabolic problems do occur in both cancer
and ASDs. It is well known that tumor cells have abnormal glucose metabolism [24]. Regarding
ASDs, studies have shown that many people with ASDs are at risk of developing or having meta-
bolic problems as comorbidities [25–27], and maternal metabolic conditions have been recognized
as contributing susceptibility to ASDs [28–30]. These documented linkages lend enough plausibil-
ity to the idea that ASDs and cancer may be either related at a metabolic level—or at least have
marked parallels in contributory mechanisms—including potentially through involvement in both
of MAPK signaling regulated metabolic processes, for us to suggest that further investigation to
more systematically assess this possible linkage via metabolism would be warranted.
Calcium signaling dysregulation in ASDs
The enrichment analysis of SFARI genes showed the calcium signaling pathway to be the most
enriched, statistically significant pathway. This is consistent with the results from recent ASD
studies that used genome-wide association studies (GWAS) data for enrichment analysis
[5,31]. GWAS examines genetic variants (typically focusing on SNPs (single-nucleotide poly-
morphisms)) in different individuals to see if any variant is associated with a trait. In contrast,
SFARI Gene integrates different kinds of genetic data that are being generated by research
studies. The fact that enrichment analyses using two different kinds of data sources both
revealed the calcium signaling pathway as highly significant strongly suggests that it is highly
involved in the molecular basis of ASDs.
It was not surprising to see that the calcium signaling pathway emerged from these analyses
as important for ASDs. Ever since mutation of the CACNA1C gene was found to be associated
with Timothy syndrome (a syndromic autism) in 2004 [32], neurogenic calcium dysregulation
has been studied in ASD research. Another study, which used GWAS data, also supported the
association of calcium channel genes with ASD [33]. The importance of the calcium signaling
pathway stands out in our data in four major ways: 1) it is the most enriched pathway; 2) it is
the second most interactive pathway in the network; 3) Ca2+ (calcium ion) participates in the
majority of the enriched pathways/collections, and 4) ASD-associated genes in the calcium sig-
naling pathway are highly involved in the network.
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It was unexpected to derive a number of cardiomyopathy pathways from ASD genes
(Table 1). After literature searching, we found that people with ASDs indeed appeared to be at
increased risk for developing heart disease [26], and reduced cardiac parasympathetic activity
was found in children with ASDs [34]. A study that analyzed rare coding variation in ASD
cases also found that ASD genes were related to congenital heart disease as well as metabolic
disorders [35].
How might the neural and cardiac phenomena mechanistically overlap in ASDs? Common
vulnerability to calcium signaling abnormalities are a potential link. Calcium signaling has a
wide range of important physiological roles including learning and memory, cellular motility,
muscle contraction, etc. [36]. In the heart, calcium is crucial for the regulation of contraction,
which is vital to heart functioning [37]. The relationship between calcium and cardiomyopathy
has been studied for years [38]. In the nervous system, calcium signaling is important in neuro-
nal synaptic transmission and plasticity [36]. Therefore, if something went wrong with calcium
signaling systemically, both cardiac and neural problems might ensue. Although identifying an
overlap between neural and cardiac genes ought to make us more attentive to potential comor-
bidities, the overlap may simply highlight how core molecular functions play roles across
diverse systems of the body and brain.
Integrated MAPK and calcium signaling
The common ASD genes in the MAPK and calcium signaling pathways are CACNA1s and
PRKCB. CACNA1s genes encode a group of proteins functioning in voltage-sensitive calcium
channels, which mediate the entry of calcium ions into excitable cells (e.g. muscle, glial cells,
neurons, etc.), and thereafter initiate a variety of calcium-dependent processes, including mus-
cle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell divi-
sion, and cell death [39]. The protein encoded by PRKCB has been reported to be involved in
many different cellular functions, which associate with tumorigenesis [40], insulin resistance
[41] and diabetic problems such as hyperglycemia-evoked blood-brain barrier damage [42], as
well as diabetic nephropathy [43] and retinopathy [44]. We thus note a theme already observed
here, in that in addition to their involvement in ASDs, both CACNA1s and PRKCB are reported
to be involved in both cancer development and metabolism-related issues.
That our integrated findings point to the process “calcium-PKC-Ras-Raf-MAPK/ERK” sug-
gests the possibility that disturbances of this process involving the overlapping genes may con-
tribute to ASDs. Notably, the mutation of RAF1, which is also an ASD-associated gene, is
additionally associated with dilated cardiomyopathy [45] and hypertrophic cardiomyopathy
[46], whose two corresponding pathways were found to be enriched and merged into collection
cardiac diseases from the pathway network. PKC and Ras-MAPK/ERK signaling are both
known to be associated with cancer [18,47] and involved in regulation of metabolism [23,48].
Taken together, we see that the process “calcium-PKC-Ras-Raf-MAPK/ERK” which our find-
ings suggest may play a key role in ASDs, is also involved in cancer, heart diseases and meta-
bolic problems, some of which are already known to co-occur with or lead to increased familial
risk for ASDs [25–27].
A systematic biological framework
Based upon the above analyses of pathway-gene relationships, we developed a visualization
linking across the different categorical groups using the results as well as the methods from
each analysis (Fig 4A and 4B). Based on the GO groups and pathways that we found to be most
enriched, we would suggest that it might well be fruitful to allocate serious attention to neuro-
active ligand-receptor activities on plasma membrane especially during nervous system
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development in ASDs. In addition, the MAPK signaling pathway and the calcium signaling
pathway, which we found to be most involved in the ASD pathway network, integrate at the
process of calcium-PKC-Ras-Raf-MAPK/ERK, and do so via ASD genes that encode proteins
functioning in multiple steps. Alterations in the activity of this process can significantly affect
its output to multiple systems and may result in serious problems throughout the whole body.
Given the increasing appreciation of ASD’s multi-scale, multi-system complexity including its
various comorbidities, such a widespread systems impact might be expected. The enriched
pathways in cancer, cardiac diseases, and metabolic diseases in the ASD Pathway Network we
derived, as well as their interactions with those functional pathways in the ASD pathway net-
work, may also at some level be associated with ASD’s heterogeneous comorbidities. All of this
suggests the need for further studies that focus on clarifying how ASDs and other complex dis-
eases are linked, guided by relationships illuminated by interactions among pertinent pathways
and reactions.
Based on the whole picture of the conclusions we have derived from our analyses (Fig 4B),
we further inferred that “environmental information processing (EIP)”might be important in
ASDs. EIP is a category of KEGG pathways (http://www.genome.jp/kegg/pathway.
html#environmental, or go to KEGG, click on “KEGG PATHWAY”, and find the category
“Environmental Information Processing” listed as number 3 under “Pathway Maps”) to which
calcium and MAPK signaling pathways and many of our other enriched pathways belong. EIP
means the procedures that cells utilize to react to environmental information and conduct con-
sequent signal transductions. For example, the calcium signaling, MAPK signaling and recep-
tor activities we have been discussing constantly react to signal molecules and changes in the
environment outside of cells, with processing of that information leading to a series of reactions
including activities inside the nucleus such as gene transcription (Fig 4C). On this basis, envi-
ronmental factors may trigger intracellular changes and eventually affect gene expression.
Environmental risk factors have been discussed in the ASD literature and various studies have
suggested their importance [49–51]. Our findings here suggested that EIP might be specifically
involved in the underlying mechanism of ASDs as well as gene or gene-function relationship to
environmental vulnerability.
Limitations and potential biases of this study
In spite of our efforts to use unbiased methods, we are aware that bias may remain in our study
on account of factors including the limitations of our techniques, the possible biases existing in
the current knowledge based databases, and the limited aggregate knowledge within the perti-
nent fields of research themselves.
Even in a database as carefully constructed as SFARI Gene [52], one can imagine a number
of possible sources of bias, such as: 1) The tendency to study genes that are related to genes
already implicated in ASDs–for example, the identification of a relationship between CAC-
NA1C and the ASD-related Timothy Syndrome sparked an interest in calcium channels more
broadly, leading to an uptick of findings about calcium channel genes in relation to ASDs. 2)
The over-representation of longer genes, documented as occurring on the SFARI gene list [53],
for reasons that include the higher probability that longer genes will contain a potential muta-
tion, as well as greater technical likelihood of capture for exome sequencing. 3) Underrepresen-
tation in the literature of emerging areas of clear importance. For example, although we now
know that more than half of the transcripts in human brain are non-protein coding RNAs
(ncRNAs), the field is only beginning to understand the contributions of ncRNA to ASDs and
to gene network function, which are therefore presently underrepresented relative to protein-
coding in the database. 4) While it is clear that genes in SFARI Gene do not all have the same
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strength of evidence for inclusion, the Gene Scoring module presently under development for
this database that would correct for this [54] is not yet completed, with many genes still
unscored, so that there is not yet a systematic, consensual way to correct for this problem.
There are further concerns regarding weighing schemes. While ideally it would be good to
evaluate the strength of the association of genes to ASDs before performing the network analy-
sis, it is also possible that such weighting schemes could introduce bias. ASD is hugely hetero-
geneous, and at present there are no known mechanisms documented to be present in every
individual who meets criteria for ASD at the behavioral level. Moreover there are no really
strong correlations between any biomarkers and any of the core behavioral features used to
define ASD. These are among the reasons why so far as we know, there is no gold standard for
ASD gene scoring in the research community, especially when studying the whole massively
Fig 4. A systematic biological framework. The flow chart in a, summarizes the analyses and related results. The conclusions are visualized into a cellular
model in b. The relationship between genes, gene products, environmental information processing and phenotypes is schematized in c.
doi:10.1371/journal.pone.0153329.g004
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heterogeneous spectrum. This is particularly important regarding so-called “idiopathic autism”
which at present constitutes the majority of individuals with ASDs and whose genetic bases are
not yet characterized.
Because of this, we are not able to imagine any criterion for scoring “relevance to ASD” that
could be defended as equally relevant to all possible subtypes of ASD. Yet presently, based on
DSM-V criteria—which are behaviorally and not biologically or genetically based—so long as
someone meets criteria for ASD, they have ASD legitimately—that is, there is no rigorous way to
deem some types of fully and reliably diagnosed ASD as being more real than other types. On this
basis as well as considerations earlier described, we feel that it would be premature to apply scor-
ing to this set of genes regarding relevance. Moreover, we were concerned that including the score
of the ASD genes based on the genetic defects associated with syndromic autism variants could
lead to excluding or underweighting potential important genes pertinent to other types of ASD.
There is another potential bias from the KEGG database we used. KEGG PATHWAY is a
representation of our knowledge regarding molecular interaction and reaction networks.
KEGG’s inclusion of numerous cancer pathways maps in their collections may possibly reflect
the intensive research efforts devoted to cancer. To limit the impact of this possible bias upon
our outcomes, we applied the redundancy control to the enriched pathways and merged the
highly overlapped pathways into collections. However, our finding that the cancer pathway/
collection is the most represented disease pathway might still reflect bias.
The outcome of the methods we used to determine the most interactive or hub pathways
specifically for ASDs might reflect yet further bias. Although some pathways might interact
with more pathways in general and although this might contribute to their levels of interactiv-
ity in our network, we did not normalize for this because we could not locate any existing stan-
dards to guide such normalization properly and thoroughly. Given the limitations of our
knowledge at present, attempted normalization might result in a net addition rather than loss
of artifact. As an example, MAPK and calcium signaling pathways play important roles in cells,
leading to their high interactivity with other pathways in general, and this may introduce bias
in interaction analysis. Even so, it remains striking that MAPK signaling pathways interacted
with half (20 out of 40) of the pathways/collections in our ASD pathway network. Whether or
not this is a “bias,” it still remains germane to gain further knowledge regarding how these
pathways may contribute to ASD mechanisms.
In the end the best protection against bias is to acknowledge its possible sources and to pres-
ent our data modestly with the aim of contributing to further inquiry.
Conclusion
In summary, based upon our analyses the MAPK signaling and calcium signaling pathways,
particularly the overlapping process “calcium-PKC-Ras-Raf-MAPK/ERK” were found to be
strongly associated with ASDs. Both pathways play a central role in a large range of biological
processes, whose activities, when abnormal, may compromise biological output and contribute
not only to features of ASD themselves but also to a range of other vulnerabilities. It seems
quite possible that ASDs may well to a significant extent arise, or emerge, from vulnerabilities
related to a set of pleiotropic genes that are also associated with multiple co-morbid systemic
issues and that also overlap with other conditions.
The results generated by our emphasis upon gene function leads us to reflect that part of the
genetic contributions to ASD pathogenesis may arise from functional disturbances of the pro-
cesses in which these genes are involved, with such disturbances potentially originating from a
variety of reactions and processes changing gene and pathway function, since it is the ensemble
of these factors that in the end shapes the phenotype.
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Our intention is to give “the lay of the land” within the terms of some of the best resources
presently available, and at their current state of development—and not claim discovery of any
absolute final truths—we chose to “let the data speak for itself” and offer it up to the commu-
nity of researchers as one step in a much larger and more collective research enterprise. If our
results point any researcher toward a fruitful line of inquiry that might otherwise not have
been considered, we will consider that our efforts were well rewarded.
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